Ipamorelin

Ipamorelin is a designed molecule rather than a natural sequence or a fragment of one. Its five residues include alpha-aminoisobutyric acid, a non-proteinogenic amino acid, and two D-configured residues — D-2-naphthylalanine and D-phenylalanine — with a C-terminal amide.

Those design choices are deliberate. D-amino acids and non-standard residues are not substrates for the proteases that recognise natural L-peptides, so the molecule resists degradation that would rapidly clear a conventional pentapeptide. It also means the material behaves differently from a standard peptide in ways worth checking rather than assuming.

Functionally it targets GHS-R1a, the receptor for ghrelin. The literature emphasises selectivity: earlier secretagogues in the same class showed activity at additional endocrine axes, and ipamorelin was characterised as substantially more confined in its receptor engagement.

Published work covers receptor binding and functional selectivity at GHS-R1a, comparisons against other secretagogues in the same class, and studies of secretion dynamics in animal models. There is also a structural-chemistry literature examining how the non-standard residues contribute to receptor engagement and stability.

Ipamorelin is commonly studied and supplied alongside CJC-1295 because the two engage complementary pathways — ghrelin receptor and GHRH receptor. Research interest in the combination stems from that mechanistic complementarity.

Ipamorelin is prohibited in sport under the World Anti-Doping Agency list and is not an approved medicine in any jurisdiction. VaultLabs supplies it strictly for in vitro research and makes no claims about physiological effects.

Release is by chromatographic analysis against a stated purity specification, with the dual-component kit released under LC-MS. For a peptide containing D-residues, note that standard reversed-phase methods do not distinguish stereochemistry — a D-to-L substitution can be chromatographically invisible, so identity confidence rests on the manufacturing chain and mass analysis rather than the chromatogram alone.

The same blind spot applies to mass. A D-amino acid and its L counterpart are isomers with identical mass, so neither HPLC nor routine mass spectrometry will separate them. Distinguishing them requires a method chosen for the purpose, such as chiral chromatography or amino-acid analysis after hydrolysis. Most purchasing laboratories will not run that routinely, which is why the credibility of the synthesis route matters more for this peptide than for a conventional L-sequence.

Store sealed lyophilised vials at 2–8 °C, protected from light and moisture, and equilibrate before opening. After reconstitution, prepare close to the point of use, record diluent and date, and keep freeze-thaw cycles low. The non-standard residues make the molecule resistant to proteolysis but not to hydrolysis, oxidation or aggregation, so the usual solution-handling discipline still applies.

Ipamorelin is not an approved medicine in the United Arab Emirates or elsewhere and is not supplied for human or veterinary use. Orders are accepted against a research-use declaration retained in the order record.

VaultLabs catalogs ipamorelin within a dual-vial kit alongside CJC-1295, with each component documented separately.

Pituitary somatotroph assays

Selective GH release comparisons

Combination studies with GHRH analogs

Receptor binding characterization

2–8 °C (lyophilized, sealed)

2–8 °C lyophilized sealed storage. Transfer promptly to laboratory environment after UAE delivery.

Standard peptide cold storage protocols apply. Limit reconstituted solution hold times per validated SOP.